1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis: COMMENTARY

Jamal, Sophie A.
January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p10
Academic Journal
This article comments on a study conducted to examine the efficacies of alendronate and parathyroid hormone (PTH) in increasing bone mineral density (BMD) in osteoporosis. In the study, researchers reported that the increases in BMD observed after 1 year of PTH were lost if therapy was stopped but could be maintained if treatment with PTH was followed by the introduction of alendronate. Researchers also addressed whether combination therapy followed by alendronate for 1 year was superior to other regimens. With the caveat that the study did not include a group treated with PTH alone for 2 years, there was no apparent advantage to combination therapy.


Related Articles

  • Targeting Vascular Niche by Parathyroid Hormone. Pagliarulo, Caterina; Salvatore, Paola; Napoli, Claudio // Current Medicinal Chemistry;2008, Vol. 15 Issue 28, p2984 

    Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together...

  • Recombinant Full-Length Parathyroid Hormone (1-84): A Viewpoint by James Whitfield. Whitfield, James // Drugs;2006, Vol. 66 Issue 18, p2382 

    â–´ The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer.â–´ Fentanyl is rapidly absorbed from FBT...

  • Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.  // CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p48 

    Focuses on the clinical practice guidelines published by Osteoporosis Canada for the diagnosis and management of osteoporosis in Canada. Evidence for the use of anti-resorptive agents in the management of osteoporosis in 2002; Formation of new bone due to anabolic agents; Review of trials...

  • Recombinant Full-Length Parathyroid Hormone (1-84). Moen, Marit D.; Scott, Lesley J // BioDrugs;2007, Vol. 21 Issue 3, p205 

    The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // OB/GYN Clinical Alert;Apr2007, Vol. 23 Issue 12, p1 

    The article offers news briefs on issues related to medical care. Two clinical studies were conducted in England to examine the effect of inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). The U.S. Food and Drug Administration (FDA) has approved...

  • Persistence with weekly alendronate therapy among postmenopausal women. Lo, J.; Pressman, A.; Omar, M.; Ettinger, B. // Osteoporosis International;Jun2006, Vol. 17 Issue 6, p922 

    Introduction: Although clinical trials indicate that oral bisphosphonates reduce osteoporotic fracture risk, compliance with bisphosphonate therapy in practice is suboptimal, with 1-year discontinuation rates exceeding 50%. Methods: We conducted a retrospective cohort study among female members...

  • Bone of contention. Lynch, Elizabeth // Nursing Standard;3/17/2004, Vol. 18 Issue 27, p16 

    Reports on the use of alternatives to hormone replacement therapy to treat osteoporosis. Advise from the Medicines and Healthcare products Regulatory Agency in Great Britain; Non-hormonal options that are just as effective in lessening the risk of osteoporosis; Alternatives include the...

  • bmj updates.  // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311 

    The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone...

  • Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Tezval, M.; Stuermer, E. K.; Sehmisch, S.; Rack, T.; Stary, A.; Stebener, M.; Konietschke, F.; Stuermer, K. M. // Osteoporosis International;Feb2010, Vol. 21 Issue 2, p251 

    We have examined the changes induced in the trochanteric region of femur of ovariectomized rat after administration of estradiol and p.arathyroid hormone. We have developed a reproducible biomechanical test and produced trochanteric fractures to evaluate stiffness and strength of this region in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics